Industry Roundtable: Neurotech Execs Discuss Innovation, Challenges, Next Steps (part 3 of 4)
This article was originally published in The Pink Sheet Daily
Executive Summary
Panelists discuss asset valuation, the scarcity of viable candidates in some parts of the neuro sector and the need for novel ways of funding early development.
You may also be interested in...
Industry Roundtable: Neurotech Execs Discuss Innovation, Challenges, Next Steps (part 4 of 4)
Can drug companies, government and academia solve the big problems together without cries of conflicted interest?
Industry Roundtable: Neurotech Execs Discuss Innovation, Challenges, Next Steps (part 4 of 4)
Can drug companies, government and academia solve the big problems together without cries of conflicted interest?
Industry Roundtable: Neurotech Execs Discuss Innovation, Challenges, Next Steps (part 2 of 4)
In part II of a series, panelists discuss venture capital, NIH grants, SBIR and foundation funding, as ways to support discovery.